[Risk-benefit assessment and value of beta-2-sympathomimetic drugs in asthma therapy].
Schulz
V
V
Thoraxklinik der LVA Baden, Heidelberg.
Ulmer
W T
WT
Kleinsorge
H
H
D000280:Administration, Inhalation; D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D016535:Bronchial Hyperreactivity / Q000139:chemically induced / Q000401:mortality; D006801:Humans; D012307:Risk Factors; D015996:Survival Rate
D000318:Adrenergic beta-Agonists
Nutzen-Risiko-Einschätzung und Stellenwert der beta 2-Sympathikomimetika in der Asthmatherapie.